AIBullisharXiv – CS AI · Jun 257/10
🧠OncoSynth introduces a causally-aware machine learning framework that generates high-fidelity synthetic patient cohorts for oncology research, reducing treatment effect estimation errors by up to 66% at the population level. The framework addresses critical limitations in healthcare data sharing by preserving causal relationships between covariates, treatments, and outcomes, enabling reliable precision medicine research without requiring direct access to restricted patient data.
GeneralBullishFortune Crypto · May 317/10
📰Researchers have developed daraxonrasib, an experimental drug that nearly doubles survival time for advanced pancreatic cancer patients by targeting a mutated protein present in over 90% of cases. This breakthrough addresses a protein target that remained untreatable for decades, offering significant hope to patients with one of cancer's most aggressive forms.
AIBullisharXiv – CS AI · May 127/10
🧠Researchers have developed EpiGraph, a comprehensive knowledge graph containing 24,324 entities and 32,009 evidence-grounded triplets from 48,166 peer-reviewed papers to improve AI-driven epilepsy diagnosis and treatment. The accompanying EpiBench benchmark demonstrates that integrating structured clinical knowledge into large language models significantly enhances clinical reasoning, with improvements up to 41% in pharmacogenomic applications.
AIBullisharXiv – CS AI · Mar 46/103
🧠Researchers developed a Neuro-Symbolic Agentic Framework combining machine learning with LLM-based reasoning to predict colorectal cancer drug responses. The system achieved significant predictive accuracy (r=0.504) and introduces 'Inverse Reasoning' for simulating genomic edits to predict drug sensitivity changes.
AIBullisharXiv – CS AI · Jun 116/10
🧠Researchers introduce OmniBioTwin, a modular framework for health digital twins that integrates multiple biological scales through a seven-layer architecture. The system demonstrates how molecular, cellular, and organ-level computational models can be coupled together, using GLP-1 signaling pathways in Alzheimer's disease as a proof-of-concept application.
AINeutralarXiv – CS AI · Jun 46/10
🧠Researchers introduce YOTO, an end-to-end machine learning framework that simultaneously selects compact gene subsets and performs prediction tasks in single-cell transcriptomic analysis. The differentiable architecture enforces sparsity and uses multi-task learning to improve biomarker discovery while outperforming existing feature selection methods.
AINeutralarXiv – CS AI · Jun 26/10
🧠Researchers have developed a protocol for an AI-driven system that uses CT imaging to predict the risk of anastomotic leak—a serious complication in colorectal cancer surgery. The framework integrates deep learning analysis of vascular features with a case-retrieval tool to support surgical decision-making, offering a reproducible methodology for hospitals and universities to implement precision surgery tools.
AINeutralBlockonomi · May 296/10
🧠Tempus AI (TEM) stock declined 1.66% following FDA authorization for its xT CDx tumor-only cancer diagnostic test, a significant milestone in oncology that failed to drive positive market sentiment. The disconnect between regulatory approval and stock performance suggests investor focus may be on profitability, competitive positioning, or broader market conditions rather than product validation alone.
AIBullisharXiv – CS AI · May 296/10
🧠Researchers developed a multimodal AI framework that combines cardiac MRI imaging, clinical metrics, and medical text records to improve heart failure prognosis prediction and treatment planning. The integrated approach demonstrates superior accuracy compared to single-data-source algorithms, addressing a critical gap in managing this leading cause of global mortality.
AINeutralarXiv – CS AI · May 286/10
🧠Researchers present a novel causal discovery framework that combines multiple structure learning algorithms with heterogeneous effect estimation to identify drivers of undesirable health outcomes across patient subpopulations. Validated through healthcare applications examining emergency department revisits and hospital readmissions, the framework reveals that intervention effectiveness varies significantly by patient characteristics, prioritizing chronic disease management and care coordination as key targets.
AINeutralGoogle DeepMind Blog · May 166/10
🧠Filippo Menolascina leverages Co-Scientist AI to accelerate the discovery of liver disease mechanisms and identify new treatment options. The research aims to explain why certain existing drugs are effective only for specific patient populations, potentially enabling more personalized therapeutic approaches.
AINeutralarXiv – CS AI · May 116/10
🧠Researchers introduce Causal EpiNets, a neural network framework that improves estimation of individual treatment effects using Probability of Necessity and Sufficiency bounds. The method resolves critical limitations in finite-sample estimation by guaranteeing structural constraint satisfaction and correcting extremum bias, achieving better coverage and validity than standard plug-in estimators.
AINeutralarXiv – CS AI · May 116/10
🧠Researchers introduce RelAge-GNN, a graph neural network framework that models complex biological relationships among DNA methylation sites to improve aging clock predictions. The method outperforms existing approaches in estimating biological age and shows enhanced sensitivity for detecting age acceleration in disease cohorts, with interpretability analysis revealing which relationships and CpG sites drive predictions.
AIBullishBlockonomi · May 76/10
🧠Roche Holding AG announced a $750 million acquisition of PathAI to strengthen its AI-powered cancer diagnostics and digital pathology capabilities, driving a 1.55% stock increase. The deal represents a strategic investment in artificial intelligence-driven healthcare solutions for precision medicine applications.
AINeutralarXiv – CS AI · Mar 37/106
🧠Researchers developed a machine learning approach combining Virtual Twins method with survLIME to identify patient subgroups who respond differently to treatments in clinical trials. The method achieved 0.77 AUC for identifying treatment responders in colorectal cancer trials, finding genetic mutations, metastasis sites, and ethnicity as key response factors.
$CRV
AIBullisharXiv – CS AI · Feb 276/107
🧠Researchers have developed an atlas-free Brain Network Transformer (BNT) that uses individualized brain parcellations from subject-specific fMRI data instead of standardized brain atlases. The approach outperformed existing methods in sex classification and brain age prediction tasks, offering improved precision and robustness for neuroimaging biomarkers and clinical diagnostics.
AIBullishGoogle Research Blog · Oct 166/104
🧠DeepSomatic is an AI tool developed to identify genetic variants in tumor samples, advancing cancer research and precision medicine capabilities. This represents a significant application of artificial intelligence in healthcare diagnostics and genomic analysis.
AINeutralGoogle Research Blog · Aug 64/107
🧠DeepPolisher represents a new AI-driven approach to genome polishing that significantly improves the accuracy of genomic sequencing data. This advancement could enhance the quality and reliability of genomic research foundations across various scientific and medical applications.
